Stocksigma LogoStocksigma Logo

Sun Pharma Investor Presentation: Financial Performance and Strategic Highlights

Sun Pharma reported Q1 FY27 gross sales of Rs 151,836 mn, up 10.1% YoY, driven by India formulations (+16.0% YoY to Rs 54,749 mn) and Emerging Markets

Sun Pharma Investor Presentation: Financial Performance and Strategic Highlights

Sun Pharmaceutical Industries Ltd 路 Investor Presentation 路 23 Sept 2026, 1:03 am

Sun Pharma Investor Presentation: Financial Performance and Strategic Highlights Sun Pharma reported Q1 FY27 gross sales of Rs 151,836 mn, up 10.1% YoY, driven by India formulations (+16.0% YoY to Rs 54,749 mn) and Emerging Markets (+15.4% YoY to Rs 29,456 mn). EBITDA reached Rs 44,177 mn with a 28.9% margin, while adjusted net profit grew 3.1% YoY to Rs 30,894 mn. For FY26, sales totaled Rs 582,201 mn (+11.9% YoY) with Innovative Medicines contributing 22% (USD 1,420 mn). As of 7th Sep'26, market capitalization stood at USD 48 Bn (Rs 4,545 Bn).

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements